Clinical and Biochemical Signs of Polycystic Ovary Syndrome in Young Women Born Preterm

Marika Paalanne¹-³, Marja Väääräsmäki¹,², Sanna Mustaniemi¹,² Marjaana Tikanmäki¹,², Karoliina Wehkalampi¹,³, Hanna-Maria Matinolli¹,⁴,⁵, Johan Eriksson¹,⁶,⁷,⁸, Marjo-Riitta Järvelin²,⁹, Laure Morin-Papunen², Eero Kajantie¹,²,³,¹⁰

¹Finnish Institute for Health and Welfare, Population Health Unit, Oulu and Helsinki, Finland; ²PEDEGO Research Unit (Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics, and Gynecology), Medical Research Center Oulu (MRC Oulu), Oulu University Hospital and University of Oulu, Oulu, Finland; ³Children’s Hospital, Helsinki University Hospital and University of Helsinki; ⁴Research Center for Child Psychiatry, University of Turku, Turku, Finland; ⁵INVEST Research Flagship, University of Turku, Turku, Finland; ⁶Folkhälsan Research Center, Helsinki, Finland; ⁷Department of General Practice and Primary Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; ⁸National University of Singapore, Yong Loo Lin School of Medicine, Department of Obstetrics and Gynecology, Singapore; and Singapore Institute for Clinical Sciences, Agency for Science, Technology, and Research, Singapore. ⁹Imperial College, London, United Kingdom; ¹⁰Norwegian University of Science and Technology, Department of Clinical and Molecular Medicine, Trondheim, Norway.

Corresponding author’s postal and email address: Oulu University Hospital, Department of Pediatrics and Adolescence, P.O. Box 23, 90029 OYS, Finland; marika.paalanne@ppshp.fi.

A short title: PCOS in Women Born Preterm

Key words: premature birth, testosterone, sex hormone-binding globulin, free androgen index, polycystic ovary syndrome, hyperandrogenism.

Word count: 3566
Abstract

Objective: It has been suggested that adverse early life exposures increase the risk of developing polycystic ovary syndrome (PCOS) in later life. We hypothesized that women born preterm would have more biochemical and clinical signs of PCOS than women born at term.

Design: The ESTER Preterm Birth Study participants were born in Northern Finland, and identified from the Northern Finland Birth Cohort and the Finnish Medical Birth Register. Altogether, 74 women born very or moderately preterm (<34 gestational weeks, VMPT), 127 born late preterm (at 34–36 weeks, LPT), and 184 born full term (≥37 weeks, controls) were included in the analysis (mean age 23.2y).

Methods: We measured serum total testosterone and sex hormone binding globulin (SHBG) and calculated free androgen index (FAI). PCOS according to the clinical and biochemical signs was defined either as hirsutism and oligoamenorrhea (via questionnaire), or as oligoamenorrhea and elevated testosterone levels (>2.4 nmol/l).

Results: Women born VMPT/LPT exhibited 33.0% (8.7, 62.8)/16.4% (-2.0, 38.1) higher testosterone, 28.5% (5.3, 45.9)/24.1% (5.6, 38.9) lower SHBG levels, and 64.6% (19.4, 127.1)/42.5% (11.1, 82.9) higher FAI than controls after adjusting for age and recruitment cohort, maternal BMI, smoking, and pregnancy disorders, parental education, history of hypertension, diabetes, myocardial infarction or stroke, and subject’s birth weight SD. Odds ratios for having PCOS were 1.67 (0.44, 6.23)/3.11 (1.26, 7.70).

Conclusions: Women born preterm have a more hyperandrogenic hormonal profile, and those born LPT are approximately three times more likely at risk to have PCOS compared to women born at term.

Keywords: premature birth, late preterm birth, testosterone, sex hormone binding globulin, free androgen index, polycystic ovary syndrome

Introduction

There is increasing evidence that adults born with very low birth weight (<1500 g, VLBW) or very preterm (<32 gestational weeks, GW) show enhanced cardiometabolic risk factors including elevated blood pressure (1,2) and lower insulin sensitivity (1,3,4). Some of these risks are also present in the large group of young adults born late preterm (34–36 GW), which is consistent with a dose–response relationship between degree
of prematurity and non-optimal metabolic characteristics such as higher body fat percentage and higher waist circumference, lower insulin sensitivity, and elevated risk of metabolic syndrome (5).

The metabolic characteristics that are associated with an increased risk of metabolic syndrome, type 2 diabetes, and cardiovascular disease include hyperandrogenism and polycystic ovary syndrome (PCOS). PCOS is one of the most common endocrine disorders; it affects about 5–18% of women worldwide depending on ethnicity and on the criteria applied (6-8).

It has been suggested that the fetal environment, such as intrauterine growth retardation, might program individuals for the development of PCOS later in life (9,10). For example, some retrospective studies have shown that girls born small for gestational age (SGA) are at a higher risk of developing early pubarche, early menarche, and PCOS (11,12), but published results have been controversial (13). Women born preterm with VLBW had similar reproductive hormone levels than their peers born at term in Swedish cohort (14). However, women born <32 weeks had elevated levels of adrenal androgens (DHEA sulfate and androstenedione), particularly when born SGA (15). The associations of preterm birth with PCOS been little studied in women born preterm (<37 weeks) even though 11% of all babies, about 14.9 million annually worldwide, are born preterm (16).

We hypothesized that women born preterm present more clinical and biochemical signs of PCOS than women born at term.

**Materials and Methods**

The participants come from the ESTER Preterm Birth Study, including 753 young adults identified from the Northern Finland Birth Cohort (NFBC, born 1985–1986) or from the Finnish Medical Birth Register (FMBR, born 1987–1989 in the same area) who participated in a clinical study in 2009–2011 and had confirmed gestational ages (5). Of them, 394 (52.3%) were women. After excluding nine women who reported cerebral palsy, mental disability, and/or other severe physical disability, 74 women born very or moderately preterm (VMPT, born before 34 GW), 127 born late preterm (LPT, born at 34–36 GW), and 184 born full term (controls, born ≥37 GW) were included in the analysis. In addition, those who were pregnant (n = 18) were excluded from the analysis of weight, body mass index (BMI), body fat percentage, sex hormone binding globulin (SHBG), and testosterone. Details of the nonparticipation analysis have been published previously (5).
Perinatal data

The perinatal data from the participants recruited from the NFBC came from the cohort database, originally collected from medical records. We collected corresponding data from those invited through the FMBR from their hospital and maternal welfare clinic records. We independently confirmed the length of gestation and diagnoses of maternal gestational diabetes (GDM), hypertension (gestational or chronic), or pre-eclampsia (including superimposed) according to prevailing criteria by reviewing their original hospital records. We calculated birth weight standard deviation (SD) scores according to Finnish birth weight standards. We defined “small for gestational age” as more than 2 SD below the mean for sex and length of gestation.

Clinical examination

The subjects attended the clinic at 0700–0900 h and were examined by two trained study nurses. Height (cm) was measured three times. Waist circumference (cm), measured midway between the lowest rib and the iliac crest, was measured twice. The mean height and weight was calculated. We used a segmental multi-frequency bioelectrical impedance (InBody 3.0, Biospace Co., Seoul, Korea) to assess weight (kg) and body composition, including fat mass (kg) and percentage of body fat (%). BMI was calculated (kg/m$^2$).

Blood samples were collected after overnight fasting and two hours after a 75 g oral glucose load. Serum insulin (µU/mL) was measured at three points (0 min, 60 min, and 120 min). Serum total testosterone (nmol/l) and SHBG (nmol/l) concentrations were measured to assess hyperandrogenemia using an Architect ci8200 analyzer (Abbott Laboratories, USA) with 2nd generation chemiluminescent microparticle immunoassay, which has been developed to improve accuracy at low concentrations among women and shows similar discriminatory power for PCOS as liquid chromatography-mass spectrometry, the reference method (19) (Abbott Laboratories, USA) at the Biochemistry laboratory of the Genetic and Biomarker Unit in the National Institute for Health and Welfare. According to the reference values of the reagent manufacturer, testosterone levels >2.4 nmol/l were considered elevated. The homeostatic model assessment of insulin resistance (HOMA-IR) and free androgen index (FAI) were calculated: FAI = (testosterone/SHBG) x 100.

The participants completed questionnaires covering their medical histories and medications (including use of oral contraceptives), family medical history, socioeconomic status, and lifestyles. Socioeconomic status was assessed as the educational attainment of the more highly educated parent and...
was categorized in four levels (dummy coded). Self-reported physical activity levels were converted to total metabolic equivalent hours per week (MET/h/wk) (21).

Definition of PCOS according to the clinical and biochemical signs

Several questions were asked to assess hirsutism, a clinical manifestation of androgen excess: “Do you have excessive growth of hair? Do you remove facial hair regularly (excluding the eyebrows)? How many times per month?” Hirsutism was considered present if a woman had excessive growth of hair or removed facial hair regularly at least four times per month. To assess menstrual cycle irregularity, one question inquiring about the minimum and maximum length and another inquiring about the regularity of the menstrual cycle without hormonal contraception was asked: “Is your menstrual cycle often (more than twice per year) longer than 35 days?” (22). Oligomenorrhea was defined if the participants answered “yes” to the aforementioned question, and irregular menses were defined if the length of the menstrual cycle regularly varied over seven days or if the participant had been treated for irregular menstrual cycle.

According to the Rotterdam definition and the International guidelines, the diagnostic criteria of PCOS require women to have two out of three of the following manifestations: 1) oligo- or anovulation, 2) clinical and/or biochemical signs of hyperandrogenism, and 3) polycystic ovaries at ultrasound (23,24). As the ultrasound of the ovaries had not been performed in the study population, the group referred in the present study as “women with PCOS” included the participants having 1) oligo- or anovulation and hirsutism or 2) oligo- or anovulation and elevated testosterone levels (>2.4 nmol/l).

Ethics

The research protocol was approved by the Coordinating Ethics Committee at Helsinki and Uusimaa Hospital District, and all participants provided written informed consent.

Statistical methods

The data were analyzed using SPSS 22.0. Crude differences between groups were assessed with Dunnett’s t-test and Pearson’s chi-square test. Differences in continuous and categorical variables were assessed with linear and logistic regression.

The main outcome variables of the study are testosterone, SHBG and FAI levels and PCOS according to the clinical and biochemical signs. Regression Model 1 included age and source cohort (NFBC
or FMBR). Model 2 comprises variables in Model 1 and parental and prenatal confounding factors including parental educational attainment as a proxy for childhood socioeconomic position, maternal BMI, smoking, hypertension, pre-eclampsia and GDM during pregnancy, and subject’s birth weight. SD scores were used as indicators of fetal conditions during pregnancy, and parental history of hypertension, diabetes, and myocardial infarction or stroke were used as proxies for genetic susceptibility. Model 3 includes both the confounders and mediators and it comprises variables in Model 2 and current characteristics, including body fat percentage, physical activity, smoking, and hormonal contraception. We did not adjust the results with the phase of the menstrual cycle, because it has been shown that there is only a low intraindividual variability of SHBG over the menstrual cycle (25). We conducted an additional analysis by excluding those born SGA to ensure that the association between preterm birth and hyperandrogenism did not depend on intrauterine growth retardation.

**Results**

Perinatal and neonatal characteristics of subjects and educational and medical history of parents are described in Table 1.

Women born VMPT and LPT were slightly younger but had similar BMIs as the controls (Table 2). Women born LPT had higher waist circumference, serum concentrations of fasting insulin, and 120 min insulin in oral glucose tolerance test and HOMA-IR than controls. The differences in insulin levels and HOMA-IR were not statistically significant when adjusted for covariates. Women born VMPT more often reported regular smoking.

**Hyperandrogenemia**

The mean absolute values of testosterone, SHBG, and FAI are presented in Table 2 and Figure 1. In the linear regression models, women born VMPT had 18.1% (95% CI 3.0, 25.4) higher testosterone, 25.4% (95% CI 4.4, 41.8) lower SHBG levels, and 52.1% (95% CI 14.2, 102.7) higher FAI than women born at term after adjustment for age and recruitment cohort (Model 1, Table 3). Women born LPT had 10.5% (-3.1, 26.1) higher testosterone, and 19.6% (95% CI 1.6, 34.4) lower SHBG levels, and 32.7% (95% CI 5.0, 67.8) had higher FAI than their peers born at term (Model 1, Table 3). The differences were larger after adjusting for parental and prenatal factors (Model 2, Table 3). After adjusting for both parental and prenatal factors and current characteristics (Model 3, Table 3), the differences between women born VMPT and the controls...
increased regarding testosterone levels; they were attenuated regarding SHBG levels and FAI. However, with the same adjustments, the differences in SHBG levels and FAI between the LPT group and the controls remained similar (Model 3, Table 3).

When gestational age at birth was used as a continuous variable, a one-week higher gestational age was associated with a 2.8% (95% CI 0.1, 5.4) lower FAI (Model 1). The difference attenuated after adjusting for parental and prenatal factors (Model 2) and became statistically nonsignificant after adjusting for all covariates (Model 3). However, there was no statistically significant linear association between gestational age and total testosterone or SHBG level.

PCOS according to clinical and biochemical signs

PCOS was present in 5.4% of the women in the VMPT group, 12.6% in the LPT group, and 7.6% in the control group. Odds ratio (OR) for PCOS was 0.78 (95% CI 0.24, 2.49) in VMPT group and 0.67 (0.92, 4.39) (Model 1, Table 3). However, when adjusted for parental and prenatal confounding factors (Model 2) the ORs for PCOS were 1.67 (0.44, 6.23) for VMPT and 3.1 (1.26, 7.70) for LPT women. The ORs were higher after adjusting for all of the covariates (Model 3). We found no difference in the prevalence of PCOS between the VMPT group and the controls.

The effects of prenatal factors

In linear regression models, a one-unit-higher birth weight SD score predicted 4.5% (0.8%, 8.2%) higher total testosterone levels, 8.8% (0.7%, 16.3%) lower SHBG levels and 14.3% (4.1%, 25.5%) higher FAI (Model 2).

We conducted an additional analysis by excluding women born SGA. The mean difference in testosterone levels between the VMPT group and the controls increased after adjusting for age and recruitment cohort (Model 1) and attenuated when adjusted for parental and prenatal factors (Model 2); they were not statistically significant after adjusting all covariates (Model 3) compared to an analysis that included those born SGA. However, the differences in SHBG levels and FAI increased in both groups compared to controls after adjusting for Models 1–3; the ORs for PCOS were similar in all of the models.

Exposure to maternal GDM predicted 30.1% (95% CI 9.3, 46.2) lower total testosterone and 49.7% (95% CI 5.7, 73.2) lower SHBG levels (Model 2), but it did not have a statistically significant effect on FAI: 39.0% (95% -32.6, 186.3). Also, maternal history of type 1 or 2 diabetes predicted PCOS (OR 6.8, 95% CI 1.5, 31.9). We conducted an additional analysis by excluding the women exposed to maternal hypertension
during pregnancy, pre-eclampsia, and GDM. The results were similar, and any differences became slightly larger. However, maternal hypertensive pregnancy disorders did not predict hyperandrogenism.

Associations with body composition and hormonal contraception

In linear regression models, a 1% higher body fat percentage was associated with 0.5% (0.0, 1.1) higher total testosterone, 1.7% (95% CI 0.6, 2.9) lower SHBG and 1.9% (95% CI 0.8, 2.9) higher FAI; levels. Use of hormonal contraception were associated with 15.0% (95% CI 7.8, 21.6) lower total testosterone levels, 159.3% (95% CI 119.2, 206.8) higher SHBG levels, and 68.0% (95% CI 62.5, 72.6) lower FAI (Model 3). When hormonal contraception was not a covariate in Model 3, the difference between the preterm and control groups decreased regarding testosterone levels, but it increased regarding SHBG and FAI levels. The ORs for PCOS remained similar. We also performed a sensitivity analysis excluding the 154 women (40.0%) who used hormonal contraception. Differences in testosterone and FAI attenuated, but differences in SHBG and OR’s for PCOS remained similar, although confidence intervals were wider (Supplementary Table 1). In addition, we excluded those subjects who had given birth within six months before participating to this study (2 subjects born VMPT, 3 born LPT and 6 controls). The results remained similar (Supplementary Table 2).

Discussion

We found that women born VMPT had higher serum total testosterone, while women born VMPT and LPT had lower SHBG levels and higher FAI. The differences were larger between the VMPT group and the controls than between the LPT group and the controls, which is consistent with a dose–response relationship between gestational age at birth and hormonal levels. In addition, women born LPT had elevated risk of having PCOS according to clinical and biochemical signs when adjusted for parental and perinatal factors and/or current characteristics.

In a previous study women born with VLBW had similar levels of reproductive hormone levels compared with their controls at 26-28 years of age (14). However, the number of subjects was small (24 VLBW women, 25 controls). Also elevated adrenal androgen levels has been reported in women born before 32 GW particularly in those born SGA, but testosterone levels was not reported (15). Women born SGA (but not preterm) had a higher prevalence of hyperandrogenism and/or PCOS (11,12). In the present study, the overall prevalence of PCOS according to the clinical and biochemical signs was 8.8% (5.4% of women in the
early preterm group, 12.6% in the late preterm group, and 7.6% in the control group); this is in line with a prevalence of a 6–18% of PCOS as reported in other populations (6-8). Our results are also in line with the data of the NFBC1966 study in the same area, in which isolated oligoamenorrhea at age 31 years was reported by 11.2%, isolated hirsutism by 10.9%, and both symptoms by 4.2% of the women who returned the questionnaire (26,27).

As expected, use of hormonal contraception was associated with a less hyperandrogenic hormonal profile (lower total testosterone levels and FAI and higher SHBG levels) in the linear regression models. However, differences in the use of hormonal contraception between groups were small and not statistically significant, and adjusting for this parameter did not alter the results. We also performed a sensitivity analysis excluding women who used hormonal contraception, in which differences in testosterone concentration and FAI attenuated. However, as 40% of women used hormonal contraception, the power of this analysis was limited and the results should be treated with caution.

Mechanisms

We have previously shown in this cohort that young adults born VMPT and LPT had higher rates of obesity and higher waist circumferences and body fat percentages than their peers born at term, although this was not statistically significant in this sample (5). Adjustment for body fat percentage attenuated our main findings, and larger body fat percentage among women born preterm could be among the underlying mechanisms.

Young adults born preterm have lower insulin sensitivity than their peers born at term (1,3,4). In the whole population of the ESTER Preterm Birth Study (including men), especially LPT birth was associated with decreased insulin sensitivity (5); this was mainly explained by increased body fat (5). Similarly, in the present study including only women, those born LPT were more hyperinsulinemic (higher mean fasting and two-hour insulin levels in the oral glucose tolerance test) and insulin resistant (higher HOMA-IR) than women born at term. Women with PCOS exhibit peripheral insulin resistance (28) and compensatory hyperinsulinemia, both of which are central pathogenetic features of the syndrome (29). Insulin resistance might contribute to hyperandrogenism by several mechanisms: Insulin acts synergistically with luteinizing hormone to improve androgen production, and high levels of insulin reduce circulating SHBG levels, thereby increasing the bioavailability of testosterone. In contrast, increasing evidence suggests that an excess of androgen might also contribute to insulin resistance by favoring a predominantly abdominal distribution of
body fat and visceral adipose tissue dysfunction (30). Furthermore, abdominal adiposity and adipose tissue dysfunction may induce insulin resistance, and compensatory hyperinsulinemia favors further androgen excess, closing a vicious circle that contributes to the development of the metabolic and cardiovascular risks typically observed in women with PCOS. In line with this hypothesis, in the present study, LPT women exhibited significantly higher waist circumferences compared with controls despite having similar BMIs.

In the present study, neither low birth weight SD score nor being SGA explained the difference in clinical and/or biochemical signs of PCOS between women born preterm and women born at term. The exposure to maternal GDM in the present sample predicted lower total testosterone and lower SHBG levels, and maternal type 1 or 2 diabetes predicted PCOS according to clinical and biochemical signs in women, but this did not explain the difference between women born preterm and their peers born at term. Lower SHBG levels were also found in a parallel study which focused on maternal GDM as an exposure and included predominantly adults born at term (31). That study showed no difference in total testosterone and did not assess clinical signs of of PCOS. It is possible that the association between maternal GDM and hyperandrogenemia in the present study is specific to our sampling frame focusing on adult outcomes of preterm birth.

The development of the hypothalamus-pituitary-gonadal-axis in preterm infants is not fully understood. Girls born preterm have highly elevated FSH and LH levels and immature ovarian hormone synthesis during early infancy (32) suggesting disturbance of development of HPG-axis. The origin of PCOS is multifactorial, but there is increasing evidence of a strong genetic background (33). It has been suggested that some genetic determinants are associated with preterm birth as well as with cardiovascular diseases: Women with a history of preterm delivery have an elevated risk of cardiovascular disease (34). Also women with PCOS are at greater risk for preterm delivery and have more pregnancy disorders such as pregnancy-induced hypertension, pre-eclampsia, and GDM (35). In total, our findings support the theory that early life factors may be associated with the development of PCOS in later life.

Limitations

The number of participants in the VMPT group resulted in limited power for the analysis of dichotomous variables (PCOS according to clinical and biochemical signs). Therefore, our findings of no difference in the presence of PCOS between the VMPT group and the controls should be interpreted with caution. Other limitations include the definition of PCOS according to clinical and biochemical signs. Hirsutism should
ideally be quantified according to the modified Ferriman-Gallwey score as per common guidelines. However, this scoring was not performed during the extensive clinical examination of the cohort, which included a wide range of reproductive, cardiometabolic, mental health and functional outcomes. Hirsutism is subjective and may be easily over-reported. Nevertheless, we have previously shown that self-reported isolated hirsutism does correlate with increased androgen secretion; further, self-reported oligoamenorrhea and hirsutism can identify women with the typical endocrine and metabolic profiles of PCOS (22,36). We did not perform ultrasonography to assess the presence of polycystic ovaries (PCO). Women with PCO who might be symptom-free would exhibit milder hormonal and metabolic disorders than symptomatic women and they have been reported to show similar metabolic status than control healthy women (37). We would therefore expect that the differences between the clinical and biochemical signs of PCOS and control groups would have been similar or even greater if we would have been able to exclude women with PCO only.

Significance of the findings

The evidence of the association of preterm birth and CVD risk factors in adulthood is strong and consistent. Although metabolic and cardiovascular disturbances (including abdominal adiposity, disorders of glucose regulation, dyslipidemia, metabolic syndrome, hypertension and cerebrovascular disease) are frequent in adolescent and adult women with PCOS (28,38-40), it is still uncertain whether PCOS confers a risk of CVD through mechanisms other than overweight, insulin resistance, diabetes, and metabolic syndrome. However, recent studies indicate that impaired glucose regulation, enhanced ovarian androgen secretion, and chronic low-grade inflammation observed in premenopausal women with PCOS persist after menopausal transition, emphasizing lifelong health risks related to this syndrome (41).

Conclusion

Women born preterm have more clinical and biochemical signs of PCOS, including hyperadrogenemia, than women born at term. This is consistent with the theory that hyperandrogenemia and PCOS are in part programmed by conditions during early life, and it suggests that these conditions are not limited to those associated with intrauterine growth restriction. Together with increased levels of other cardiometabolic risk factors, the findings also argue for an increased risk of cardiometabolic disorders such as type 2 diabetes and coronary artery disease later in life in adults born preterm.
Declaration of interest, Funding and Acknowledgements

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

The ESTER study was supported by grants from the Academy of Finland (SALVE program for 2009–2012 and grants 127437, 129306, 130326, 134791 263924 and 315690 to EK), the Emil Aaltonen Foundation, the European Commission (Framework 5 award QLG1-CT-2000-001643; to MRJ and Horizon 2020 award 733280 RECAP Research for Children and Adults Born Preterm to EK), Norface DIAL 462-16-040 Award PremLife to EK, the Finnish Foundation for Pediatric Research, the Finnish Government Special Subsidiary for Health Sciences (evo), the Finnish Medical Society: Duodecim, the Jalmari and Rauha Ahokas Foundation, the Juho Vainio Foundation, the Novo Nordisk Foundation, the Signe and Ane Gylenberg Foundation, the Sigrid Jusélius Foundation, the Jenny and Antti Wihuri Foundation, and the Yrjö Jahnsson Foundation. In addition, NFBC 1986 received financial support from the Academy of Finland (grants 175617, 173454, 24300269, and 24300217); EU FP7-ENV-2008-1-226534; USA/NIH/NHLBI 1-R01-HL087679-01; RFP-RM-06-008; NorFA (50847); Thule Institute (50925); Oulu University Hospital, Oulu, Finland (24301140); and University of Oulu, Finland (24000692, 24500283).
References

1. Markopoulou P, Papanikolaou E, Analytis A, Zoumakis E, Siahanidou T., Preterm Birth as a Risk Factor for Metabolic Syndrome and Cardiovascular Disease in Adult Life: A Systematic Review and Meta-Analysis. The Journal of Pediatrics 2019 210 69-80.

2. Hovi P, Vohr B, Ment LR, Doyle LW, Mcgarvey L, Morrison KM, Evensen KA, van der Pal S, Gurau RE; APIC Adults Born Preterm International Collaboration, Brubakk AM, et al. Blood Pressure in Young Adults Born at Very Low Birth Weight: Adults Born Preterm International Collaboration. Hypertension 2016 68(4) 880-887.

3. Hovi P, Andersson S, Eriksson JG, Järvenpää AL, Strang-Karlsson S, Mäkitie O, Kajantie E. Glucose regulation in young adults with very low birth weight. New England Journal of Medicine 2007 356(20) 2053-2063.

4. Kajantie E, Strang-Karlsson S, Hovi P, Wehkalampi K, Lahti J, Kaseva N, Järvenpää AL, Räikkönen K, Eriksson JG, Andersson S. Insulin sensitivity and secretory response in adults born preterm: the Helsinki Study of Very Low Birth Weight Adults. Journal of Clinical Endocrinology and Metabolism. 2015 100(1) 244-50.

5. Sipola-Leppänen M, Vääräsmäki M, Tikanmäki M, Matinolli HM, Miettola S, Hovi P, Wehkalampi K, Ruokonen A, Sundvall J, Pouta A, et al. Cardiometabolic risk factors in young adults who were born preterm. American Journal of Epidemiology 2015 181(11) 861-73.

6. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology and Metabolism 2000 85(7) 2434-8.

7. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism 1998 83 3078–82.

8. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction 2016 31 2841–55.

9. Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. Journal of Clinical Endocrinology and Metabolism 2006 May 91(5) 1660-6.
10. Ibáñez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. *Journal of Clinical Endocrinology and Metabolism* 1998 **83**(10) 3558-62.

11. Ibáñez L, Jaramillo A, Enríquez G, Miró E, López-Bermejo A, Dunger D, de Zegher F. Polycystic ovaries after precocious pubarche: relation to prenatal growth. *Human Reproduction* 2007 **22**(2) 395-400.

12. Melo AS, Vieira CS, Barbieri MA, Rosa-E-Silva AC, Silva AA, Cardoso VC, Reis RM, Ferriani RA, Silva-de-Sá MF, Bettiol H. High prevalence of polycystic ovary syndrome in women born small for gestational age. *Hum Reprod*. 2010 Aug;25(8):2124-31.

13. Legro RS, Roller RL, Dodson WC, Stetter CM, Kunselman AR, Dunaif A. Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives. *Journal of Clinical Endocrinology and Metabolism* 2010 **95**(2) 789-99.

14. Sydsjö G, Törnblom P, Gäddlin PO, Finnström O, Leijon I, Nelson N, Theodorsson E, Hammar M. Women born with very low birth weight have similar menstrual cycle pattern, pregnancy rates and hormone profiles compared with women born at term. *BMC Womens Health* 2019 25;19(1):56.

15. Meuwese CL, Euser AM, Ballieux BE, van Vliet HA, Finken MJ, Walther FJ, Dekker FW, Wit JM. Growth-restricted preterm newborns are predisposed to functional adrenal hyperandrogenism in adult life. *European Journal of Endocrinology* 2010 **163**(4) 681-9.

16. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, Landoulsi S, Jampathong N, Kongwattanakul K, Laopaiboon M, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. *Lancet Global Health* 2019 **7**(1) e37-e46.

17. Sipola-Leppänen M, Väääräsmäki M, Tikanmäki M, Hovi P, Miettola S, Ruokonen A, Pouta A, Järvelin MR, Kajantie E. Cardiovascular risk factors in adolescents born preterm. *Pediatrics* 2014 **134**(4) e1072-81.

18. Pihkala J, Hakala T, Voutilainen P, Raivio K. Characteristic of recent fetal growth curves in Finland. *Duodecim* 1989 **105**(18) 1540-6.

19. Bui HN, Sluss PM, Hayes FJ, Blincko S, Knol DL, Blankenstein MA, Heijboer AC. Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. *Clinica Chimica Acta* 2015 **23;450** 227-32.20. Mathur RS, Moody LO, Landgrebe S, Williamson HO. Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. *Fertility and Sterility* 1981 **35**(1) 29-35.

21. Tikanmäki et al. Physical Fitness in Young Adults Born Preterm. *Pediatrics* 2016 137(1) e20151289.
22. Taponen S, Martikainen H, Järvelin MR, Laitinen J, Pouta A, Hartikainen AL, Sovio U, McCarthy MI, Franks S, Ruokonen A. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. *Journal of Clinical Endocrinology and Metabolism* 2003 **88**(1) 141-7.

23. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility* 2004 **81**(1) 19-25.

24. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Clinical Endocrinology*. 2018 **89**(3) 251-268.

25. Yeung EH, Zhang C, Albert PS, Mumford SL, Ye A, Perkins NJ, Wactawski-Wende J, Schisterman EF. Adiposity and sex hormones across the menstrual cycle: the BioCycle Study. *International Journal of Obesity* 2013 **37**(2) 237-43.

26. Koivunen R, Pouta A, Franks S, Martikainen H, Sovio U, Hartikainen AL, McCarthy MI, Ruokonen A, Bloigu A, Järvelin MR, et al. Northern Finland Birth Cohort 1966 Study. Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. *Human Reproduction* 2008 **23**(9) 2134-9.

27. Ollila MM, Piltonen T, Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, Franks S, Morin-Papunen L. Weight Gain and Dyslipidemia in Early Adulthood Associate With Polycystic Ovary Syndrome: Prospective Cohort Study. *Journal of Clinical Endocrinology and Metabolism* 2016 **101**(2) 739-47.

28. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. *Diabetes* 1992 **41**(10) 1257-66.

29. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. *Journal of Clinical Endocrinology and Metabolism* 1991 **72**(1) 83-9.

30. Escobar-Morreale HF, San Millán JL. Abdominal adiposity and the polycystic ovary syndrome. *Trends in Endocrinology and Metabolism* 2007 **18**(7) 266-72.

31. Kaseva N, Vääräsmäki M, Sundvall J, Matinolli HM, Sipola M, Tikanmäki M, Heinonen K, Lano A, Wehkalamki K, Wolke D, et al. Gestational Diabetes But Not Prepregnancy Overweight Predicts for
Cardiometabolic Markers in Offspring Twenty Years Later. *Journal of Clinical Endocrinology and Metabolism* 2019 **1;104(7)** 2785-2795.

32. Kuiri-Hänninen T, Dunkel L, Sankilampi U. Sexual dimorphism in postnatal gonadotrophin levels in infancy reflects diverse maturation of the ovarian and testicular hormone synthesis. *Journal of Clinical Endocrinology and Metabolism* 2018 **89** 85–92.

33. Castillo-Higuera T, Alarcón-Granados MC, Marin-Suarez J, Moreno-Ortiz H, Esteban-Pérez CI, Ferrebu-Carodozo AJ, Forero-Castro M, Camargo-Vill Alba G. A Comprehensive Overview of Common Polymorphic Variants in Genes Related to Polycystic Ovary Syndrome. *Reproductive Science* 2020 **10**.

34. Robbins CL, Hutchings Y, Dietz PM, Kuklina EV, Callaghan WM. History of preterm birth and subsequent cardiovascular disease: a systematic review. *American Journal of Obstetrics and Gynecology* 2014 **210(4)** 285-297.

35. Yu HF, Chen HS, Rao DP, Gong J. Association between polycystic ovary syndrome and the risk of pregnancy complications: A PRISMA-compliant systematic review and meta-analysis. *Medicine (Baltimore)* 2016 **95(51)** e4863.

36. Taponen S, Ahonkallio S, Martikainen H, Koivunen R, Ruokonen A, Sovio U, Hartikainen AL, Pouta A, Laitinen J, King V, et al. Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. *Human Reproduction* 2004 **19(5)** 1083-8.

37. Catteau-Jonard S, Bancquart J, Poncelet E, Lefebvre-Maunoury C, Robin G, Dewailly D. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? *Ultrasound in Obstetrics and Gynecology* 2012 **40(2)** 223-9.

38. Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, Andersen M. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. *European Journal of Endocrinology*. 2015 **172(5)** 627-38.

39. Azziz R. Polycystic Ovary Syndrome. *Obstetrics and Gynecology*. 2018 **132(2)** 321-336.

40. Wekker V, van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, Laven JSE, Roeters van Lennep JE, Roseboom TJ, Hoek A. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. *Human Reproduction Update*. 2020 **26(6)** 942-960.
41. Puurunen J, Piltonen T, Morin-Papunen L, Perheentupa A, Järvelä I, Ruokonen A, Tapanainen JS. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. *Journal of Clinical Endocrinology and Metabolism*. 2011 Jun 96(6)1827-34.
Table 1. Perinatal and neonatal characteristics and educational attainment and medical history of parents of women born very or moderately preterm (VMPT), late preterm (LPT), or full term (controls). Data are presented as mean ± S.D. or n (%).

|                          | VMPT, n = 74 |          | LPT, n = 127 |          | Controls, n = 184 |          |
|--------------------------|--------------|----------|--------------|----------|------------------|----------|
|                          | Values       | P-value  | Values       | P-value  | Values           | P-value  |
| Gestational age, weeks   | 31.9 ± 2.0   | <0.001   | 35.8 ± 0.8   | <0.001   | 40.0 ± 1.3       | <0.001   |
| Birth weight, g          | 1680 ± 450   | <0.001   | 2646 ± 554   | <0.001   | 3494 ± 456       |          |
| Birth weight SDS         | -1.1 ± 1.3   | <0.001   | -0.6 ± 1.4   | <0.001   | 0.0 ± 1.0        | <0.001   |
| Small for gestational age| 17 (23.0%)   | <0.001   | 17 (13.4%)   | <0.001   | 4 (2.2%)         | <0.001   |
| Multiple pregnancy       | 17 (23.0%)   | <0.001   | 16 (12.6%)   | <0.001   | 4 (2.2%)         | <0.001   |
| Maternal hypertension    | 11 (14.9%)   | 0.485    | 15 (12.1%)   | 0.024    | 21 (11.7%)       | <0.001   |
| Maternal pre-eclampsia   | 23 (31.1%)   | <0.001   | 14 (11.3%)   | 0.188    | 8 (4.4%)         | <0.001   |
| Maternal gestational diabetes| 2 (3.1%)     | 0.492    | 5 (4.2%)     | 0.342    | 3 (1.7%)         | <0.001   |
| Maternal smoking during pregnancy | 11 (15.7%) | 0.855 | 26 (21.0%) | <0.001 | 30 (16.7%) |        |
| Caesarean section        | 49 (66.2%)   | <0.001   | 35 (27.6%)   | <0.001   | 20 (10.9%)       |          |
| Parental education       |              |          |              |          |                  |          |
| Basic, less, or unknown  | 6 (8.1%)     | 8 (6.5%) | 13 (7.1%)    |          |                  |          |
| Secondary                | 47 (63.5%)   | 77 (62.5%) | 107 (58.5%) |          |                  |          |
| Lower-level tertiary     | 8 (10.8%)    | 17 (13.8%) | 23 (12.6%) |          |                  |          |
| Upper-level tertiary     | 13 (17.6%)   | 21 (17.1%) | 40 (21.9%)  |          |                  |          |
| Maternal history of hypertension | 14 (18.9%)  | 0.399 | 21 (16.5%) | 0.655 | 27 (14.7%)  |          |
| Maternal history of diabetes | 2 (2.7%)   | 0.431 | 10 (7.9%) | 0.280 | 9 (4.9%)    |          |
| Maternal history of MI or stroke | 0 (0.0%)  | N/A | 2 (1.6%) | 0.088 | 0 (0.0%)   |          |
| Paternal history of hypertension | 17 (23.0%)  | 0.209 | 17 (13.4%) | 0.480 | 30 (16.3%) |          |
| Paternal history of diabetes | 4 (5.4%)   | 0.114 | 12 (9.4%) | 0.486 | 22 (12.0%)  |          |
| Paternal history of MI or stroke | 3 (4.1%)   | 0.916 | 5 (3.9%) | 0.859 | 8 (4.3%)   |          |

* Pearson's chi-square test for categorical variables and Dunnett's t-tests in many-to-one comparisons for continuous variables, VMPT or LPT vs. controls.

MI, myocardial infarction
Table 2. Characteristics of women who were born very or moderately preterm, late preterm, and full term (controls). Data are presented as mean ±S.D. or as n (%).

| Characteristic                  | VMPT, n = 74 | LPT, n = 127 | Controls, n = 184 |
|---------------------------------|--------------|--------------|-------------------|
| Age mean, y                     | 23.0± 1.3    | 23.1± 1.2    | 23.5± 1.1         |
| Height, cm                      | 163.3 ± 5.1  | 164.6±5.7    | 163.9 ± 5.9       |
| Weight, kg                      | 62.4± 0.26   | 62.2± 0.19   | 60.7 ± 0.20       |
| BMI, kg/m²                      | 22.8 ± 0.24  | 22.4 ± 0.18  | 22.0 ± 0.19       |
| WC, cm                          | 77.3 ± 0.17  | 75.8± 0.12   | 73.6± 0.13        |
| Body fat percentage             | 28.7 ±0.30   | 27.1± 0.27   | 25.9±0.31         |
| Fasting insulin, µU/mL          | 7.66± 0.65   | 7.37±0.60    | 6.74±1.52         |
| 120 min insulin µU/mL           | 30.90 ± 0.85 | 30.84 ± 0.85 | 28.46 ± 1.88      |
| HOMA-IR                         | 0.99±0.63    | 0.96±0.60    | 0.88±1.50         |
| TS, nmol/L                      | 1.44±1.48    | 1.35±1.44    | 1.00±1.00         |
| Elevated TS levelsb             | 6 (8.8%)     | 3 (2.5%)     | 7 (4.0%)          |
| SHBG, nmol/L                    | 112.89±2 (3.22) | 142.40±2 (3.38) | 149.05±2.39      |
| Free androgen index             | 1.32±2.57    | 1.15± 2.54   | 0.87 ± 2.74       |
| *Physical activity, METh/wk     | 23.5 ± 12.7  | 24.9 ± 14.5  | 24.3± 11.9        |
| Daily smoking                   | 23 (31.1%)   | 26 (20.5%)   | 36 (19.6%)        |
| Hormonal contraception          | 24 (32.4%)   | 45 (35.4%)   | 74 (40.2%)        |
| Hirsutism                       | 11 (15.7%)   | 20 (16.7%)   | 20 (11.4%)        |
| Irregular menstrual cycle       | 34 (49.3%)   | 50 (42.7%)   | 68 (39.5%)        |
| Menstrual cycle >35 days        | 11 (16.2%)   | 13 (11.2%)   | 17 (10.1%)        |
| PCOSc                           | 4 (5.4%)     | 16 (12.6%)   | 14 (7.6%)         |

* Pearson’s chi-square test for categorical variables and Dunnett’s t-test in many-to-one comparisons for continuous variables, VMPT or LPT vs. controls; bTestosterone > 2.4 nmol/l; cPCOS according to biochemical and clinical signs; *Self reported leisure time physical activity.

HOMA-IR, homeostatic model assessment of insulin resistance; LPT, late preterm; METh, metabolic equivalent task hours; PCOS polycystic ovary syndrome; SHBG, sex hormone binding globulin; VMPT very or moderately preterm; WC, waist circumference; TS, testosterone.
Table 3. Mean differences (in percent) for sex hormone binding globulin and testosterone, and odds ratios for self-reported polycystic ovary syndrome according to the clinical and biochemical signs with 95% confidence intervals (95% CI) in women born very or moderately preterm or late preterm compared to controls born full term.

| Model | VMPT | LPT | Cases analysed, n |
|-------|------|-----|------------------|
|       | Values | Values | p-value | Values | Values | p-value |       |
| Testosterone | | | | | | | |
| 1 | 18.1% (3.0, 25.4) | 10.5% (-3.1, 26.1) | 0.017 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n̵
Figure 1. Mean differences and 95% CIs (error bars) in testosterone levels, sex hormone binding globulin (SHBG) levels and free androgen index (FAI) in women born very or moderately preterm (VMPT) and late preterm (LPT) compared with controls (zero line) adjusted for age and recruitment cohort.
**Supplementary Table 1.** Mean differences (in percent) for sex hormone binding globulin and testosterone, and odds ratios for self-reported polycystic ovary syndrome according to the clinical and biochemical signs with 95% confidence intervals (95% CI) in women born very or moderately preterm or late preterm compared to controls born full term. User of hormonal contraception excluded.

| Model | VMPT | LPT | Number of cases |
|-------|------|-----|-----------------|
|       | Mean difference or OR (95% CI) | P-value | Mean difference or OR (95% CI) | P-value | in the analysis |
| Testosterone |
| 1 | 10.2% (-2.8, 24.9) | 0.128 | 3.3% (-6.9, 14.5) | 0.542 | 217 |
| 2 | 11.4% (-3.0, 28.0) | 0.124 | 2.0% (-8.7, 13.9) | 0.729 | 202 |
| 3 | 12.7% (-2.1, 29.6) | 0.096 | 1.6% (-9.0, 13.4) | 0.781 | 195 |
| SHBG |
| 1 | -22.5% (-42.1, 4.6) | 0.084 | -18.6% (-36.0, 3.5) | 0.093 | 217 |
| 2 | -24.6% (-45.7, 4.6) | 0.090 | -20.2% (-38.6, 3.8) | 0.092 | 202 |
| 3 | -19.1% (-42.0, 12.9) | 0.210 | -19.5% (-38.0, 2.5) | 0.103 | 195 |
| FAI |
| 1 | 42.3% (2.8, 96.8) | 0.033 | 26.9% (-3.0, 65.9) | 0.082 | 217 |
| 2 | 37.9% (2.2, 114.0) | 0.038 | 27.7% (-5.0, 71.6) | 0.104 | 202 |
| 3 | 39.3% (-4.6 103.3) | 0.019 | 26.2% (-6.2, 69.7) | 0.123 | 195 |
| PCOS |
| 1 | 0.67 (0.17, 2.64) | 0.570 | 2.54 (1.01, 6.14) | 0.039 | 231 |
| 2 | 1.51 (0.33, 7.00) | 0.592 | 3.97 (1.33, 11.85) | 0.014 | 215 |
| 3 | 1.29 (0.21, 8.02) | 0.780 | 5.33 (1.61, 17.66) | 0.006 | 197 |

**Covariates in linear and logistic regression models:**

1) Age and recruitment cohort
2) Variables in Model 1 and parental educational attainment, maternal body mass index, smoking hypertension, pre-eclampsia and gestational diabetes during pregnancy; subject’s birth weight standard deviation scores; and parental history of hypertension, diabetes, and myocardial infarction or stroke
3) Variables in Model 2 and body fat percentage, physical activity and smoking

Abbreviations: FAI, free androgen index; LPT, late preterm; OR, odds ratio; PCOS, polycystic ovary syndrome (according to clinical and biochemical signs); SHBG, sex hormone binding globulin; VMPT, very or moderately preterm.
moderately preterm.
**Supplementary Table 2.** Mean differences (in percent) for sex hormone binding globulin and testosterone, and odds ratios for self-reported polycystic ovary syndrome according to the clinical and biochemical signs with 95% confidence intervals (95% CI) in women born very or moderately preterm or late preterm compared to controls born full term. The subjects who had given birth within six months before participating to the study were excluded.

| Model | VMPT | LPT | Number of cases in the analysis |
|-------|------|-----|---------------------------------|
|       | Mean difference or OR (95% CI) | P-value | Mean difference or OR (95% CI) | P-value |
| Testosterone | 1 | 13.6% (2.4, 26.1) | 0.017 | 8.1% (-0.7, 17.7) | 0.073 | 336 |
| | 2 | 18.1% (5.1, 32.8) | 0.005 | 10.4% (0.9, 20.8) | 0.031 | 311 |
| | 3 | 16.2% (3.5, 30.4) | 0.011 | 8.6% (-0.5, 18.6) | 0.064 | 301 |
| SHBG | 1 | -26.6% (-43.1, -5.4) | 0.017 | -20.5% (-35.4, -2.21) | 0.030 | 336 |
| | 2 | -30.7% (-48.1) | 0.013 | -25.4% (-40.2, -6.8) | 0.010 | 311 |
| | 3 | -19.6% (-37.3, 3.1) | 0.086 | -19.5% (-33.3, -2.8) | 0.024 | 301 |
| FAI | 1 | 54.9% (15.3, 107.9) | 0.004 | 36.0% (6.9, 72.9) | 0.012 | 336 |
| | 2 | 70.5% (22.0, 138.2) | 0.002 | 47.9% (14.5, 91.2) | 0.003 | 311 |
| | 3 | 44.4% (8.7, 91.9) | 0.011 | 35.0% (8.8, 67.4) | 0.006 | 301 |
| PCOS | 1 | 1.28 (0.45, 3.61) | 0.646 | 2.84 (1.21, 6.62) | 0.016 | 375 |
| | 2 | 2.54 (0.62, 10.46) | 0.20 | 4.18 (1.55, 11.29) | 0.005 | 328 |
| | 3 | 2.09 (0.43, 10.02) | 0.36 | 5.60 (1.86, 16.91) | 0.002 | 311 |

Covariates in linear and logistic regression models:

1) Age and recruitment cohort
2) Variables in Model 1 and parental educational attainment, maternal body mass index, smoking hypertension, pre-eclampsia and gestational diabetes during pregnancy; subject’s birth weight standard deviation scores; and parental history of hypertension, diabetes, and myocardial infarction or stroke
3) Variables in Model 2 and body fat percentage, physical activity, smoking, and hormonal
contraception

Abbreviations: FAI, free androgen index; LPT, late preterm; OR, odds ratio; PCOS, polycystic ovary syndrome (according to clinical and biochemical signs); SHBG, sex hormone binding globulin; VMPT, very or moderately preterm.